Madrigal Pharma (MDGL) option implied volatility into FDA approval
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Join SI Premium – FREE
Madrigal Pharma (NASDAQ: MDGL) 30-day option implied volatility is at 151; compared to its 52-week range of 49 to 176 into FDA approves Madrigal Pharmaceuticals' Rezdiffra.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)
- Strategy (MSTR) call put ratio 1.2 calls to 1 put as share price below $100
- GraniteShares 2x Long SpaceX Daily ETF (SPAL) call put ratio 1.9 calls to 1 put
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
